PMID- 15209190
OWN - NLM
STAT- MEDLINE
DCOM- 20041124
LR  - 20161124
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 18
IP  - 5
DP  - 2004 May
TI  - Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
PG  - 623-30; discussion 633-4, 637-8, 640
AB  - The field of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (NHL) 
      has advanced significantly over the past decade, and several 
      radioimmunoconjugates are being tested in clinical trials. Two of these 
      antibodies target CD20: yttrium-90 (Y-90)-labeled ibritumomab tiuxetan (Zevalin) 
      and tositumomab/iodine-131 (I-131)-labeled tositumomab (Bexxar). Other agents 
      target either CD22 (Y-90 epratuzumab) or human leukocyte antigen (HLA)-DR (I-131 
      Lym-1), respectively. In February 2002, Y-90-labeled ibritumomab tiuxetan became 
      the first radioimmunoconjugate to be approved by the US Food and Drug 
      Administration (FDA) for the treatment of cancer. Tositumomab/I-131 tositumomab 
      was approved in June 2003. Thus, two radioimmunoconjugates have been approved for 
      the treatment of NHL. Both agents, when administered as a single dose, have 
      produced impressive tumor response rates with an acceptable toxicity profile. The 
      main side effect is reversible myelosuppression. Radioimmunotherapy produces 
      overall response rates of approximately 80% in patients with low-grade lymphomas, 
      and 25% to 30% of patients achieve a complete remission. Lower response rates 
      (approximately 40%) have been reported in patients with large-cell lymphomas. 
      This review discusses the clinical trials of radioimmunotherapeutic agents for 
      NHL that demonstrated their safety and efficacy and outlines the current status 
      of these agents.
FAU - Ghobrial, Irene
AU  - Ghobrial I
AD  - Mayo College of Medicine, Rochester, Minnesota 55905, USA.
FAU - Witzig, Thomas
AU  - Witzig T
LA  - eng
GR  - CA87912/CA/NCI NIH HHS/United States
GR  - CA97274/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD20)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Yttrium Radioisotopes)
RN  - 4Q52C550XK (ibritumomab tiuxetan)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Antigens, CD20/immunology
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Iodine Radioisotopes/pharmacology/therapeutic use
MH  - Lymphoma, B-Cell/*radiotherapy
MH  - Radioimmunotherapy/*methods
MH  - Yttrium Radioisotopes/pharmacology/therapeutic use
RF  - 51
EDAT- 2004/06/24 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
AID - 163733 [pii]
PST - ppublish
SO  - Oncology (Williston Park). 2004 May;18(5):623-30; discussion 633-4, 637-8, 640.